Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05200923 · ClinicalTrials.gov registry record · NA
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
A NA study of Overactive Bladder and Fecal Incontinence, sponsored by MedtronicNeuro.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 7
- Study locations
NCT05200923: Recruiting NA study of Overactive Bladder and Fecal Incontinence, sponsored by MedtronicNeuro.
NCT05200923 is a NA study of Overactive Bladder and Fecal Incontinence that is actively recruiting participants, run by MedtronicNeuro. The registered enrollment target is 300 participants, above the 201-participant average among 46 other Overactive Bladder trials with a reported enrollment target (49% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05200923, a NA study of Overactive Bladder and Fecal Incontinence, is actively recruiting participants, sponsored by MedtronicNeuro.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 7
- Study locations
Study Summary
To collect physiological signals at several timepoints during the therapy evaluation period.
Primary Outcome
The proportion of subjects with evaluable signals will be summarized at each timepoint
Conditions Studied
Interventions
- DEVICE Sacral Neuromodulation
Study Locations (7)
Louisiana
- LSUHSC Department of Urology - New Orleans
- Ochsner Clinic Foundation - New Orleans
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- OhioHealth Physician's Group Urology - Hilliard
Indiana
- Indiana University Health Methodist Research Institute - Indianapolis
Minnesota
- Mayo Clinic Urology/Urogynecology Department - Rochester
Texas
- DHR Health Institute for Research and Development - Edinburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-01-18 |
| Est. Completion | 2026-12-18 |
| Phase | NA |
What NCT05200923 shows while recruiting
NCT05200923 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 201-participant average among 46 other Overactive Bladder trials with a reported enrollment target (49% higher).
The record links to 3 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which Sacral Neuromodulation is the first listed.
NCT05200923 lists 7 locations in 5 states (Louisiana, Ohio, Indiana).
Frequently Asked Questions
What is clinical trial NCT05200923 about?
NCT05200923 is a clinical study titled "Pelvic Health Electrically Evoked Recording (PEER) 2 Study". To collect physiological signals at several timepoints during the therapy evaluation period.
What is the current status of trial NCT05200923?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-01-18. Estimated completion is 2026-12-18.
What conditions does trial NCT05200923 study?
This clinical trial studies the following conditions: Overactive Bladder, Fecal Incontinence, Urinary Retention.
What interventions are being tested in trial NCT05200923?
The interventions under investigation include: Sacral Neuromodulation (DEVICE).
Who is sponsoring clinical trial NCT05200923?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05200923 being conducted?
This trial has 7 study locations across Indiana, Louisiana, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05200923's enrollment target sits among peer trials
300 7th of 46 higher than 40 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Percutaneous Nerve Evaluation Trial Time
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
RECRUITING · NA
-
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI